Biogen

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1978-01-01

Employees: 7.5K

Market Cap: $29.6B

Website: https://www.biogen.com

Introduction: Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Clinical Trials

A Study to Evaluate SAGE-217 in Participants With Essential Tremor

Phase 2

Completed

Conditions: Essential Tremor

Interventions: Drug: SAGE-217
Drug: Placebo

First Posted Date: 2016-12-01

Last Posted Date: 2023-11-28

Lead Sponsor: Biogen

Target Recruit Count: 34

Registration Number: NCT02978781

Locations: 🇺🇸
Sage Investigational Site, Fort Worth, Texas, United States

A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression

Phase 3

Completed

Conditions: Postpartum Depression

Interventions: Drug: Placebo
Drug: SAGE 217 30 mg Capsules
Drug: SAGE-217 15/20 mg Oral Solution

First Posted Date: 2016-11-30

Last Posted Date: 2023-12-15

Lead Sponsor: Biogen

Target Recruit Count: 276

Registration Number: NCT02978326

Locations: 🇺🇸
Sage Investigational Site, Orem, Utah, United States
🇺🇸
Sage Investigational SIte, Pinellas Park, Florida, United States

Study of Utilization Patterns of Dimethyl Fumarate in Germany

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: dimethyl fumarate

First Posted Date: 2016-11-21

Last Posted Date: 2017-07-19

Lead Sponsor: Biogen

Target Recruit Count: 930

Registration Number: NCT02969304

Locations: 🇩🇪
Research Site, Leipzig, Saxony, Germany

Extension Study to Evaluate the Long-Term Safety, Tolerability, and Maintenance of Effect of BIIB074

Phase 2

Terminated

Conditions: Neuropathic Pain From Lumbosacral Radiculopathy

Interventions: Drug: BIIB074

First Posted Date: 2016-11-08

Last Posted Date: 2019-02-25

Lead Sponsor: Biogen

Target Recruit Count: 302

Registration Number: NCT02957617

Locations: 🇬🇧
Research Site, London, United Kingdom
🇷🇸
Research Site 1, Belgrade, Serbia
🇷🇸
Research Site 2, Belgrade, Serbia

New Formulation and Food Effect Study of BIIB074

Phase 1

Completed

Conditions: Trigeminal Neuralgia (TN)
Other Neuropathic Pain

Interventions: Drug: BIIB074 Treatment C
Drug: BIIB074 Treatment A
Drug: BIIB074 Treatment B
Drug: BIIB074 Treatment D

First Posted Date: 2016-11-01

Last Posted Date: 2017-02-27

Lead Sponsor: Biogen

Target Recruit Count: 28

Registration Number: NCT02951221

Locations: 🇺🇸
Research Site, Daytona Beach, Florida, United States

Study to Evaluate the Efficacy and Safety of BIIB074 in Neuropathic Pain From Lumbosacral Radiculopathy

Phase 2

Completed

Conditions: Lumbosacral Radiculopathy

Interventions: Drug: BIIB074
Drug: Placebo

First Posted Date: 2016-10-17

Last Posted Date: 2018-08-15

Lead Sponsor: Biogen

Target Recruit Count: 502

Registration Number: NCT02935608

Locations: 🇸🇰
Reasearch Site, Dubnica nad Váhom, Slovakia
🇬🇧
Research Site, London, United Kingdom

A Phase 2a Study of BIIB074 in the Treatment of Erythromelalgia

Phase 2

Completed

Conditions: Primary Inherited Erythromelalgia

Interventions: Drug: BIIB074
Drug: Placebo

First Posted Date: 2016-09-28

Last Posted Date: 2018-01-10

Lead Sponsor: Biogen

Target Recruit Count: 8

Registration Number: NCT02917187

Locations: 🇺🇸
Research SIte, New London, Connecticut, United States
🇺🇸
Research Site, Morgantown, West Virginia, United States

Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab

Phase 3

Terminated

Conditions: Relapsing-Remitting Multiple Sclerosis (RRMS)

Interventions: Drug: Daclizumab

First Posted Date: 2016-08-29

Last Posted Date: 2019-09-27

Lead Sponsor: Biogen

Target Recruit Count: 41

Registration Number: NCT02881567

Locations: 🇵🇷
Research Site, Guaynabo, Puerto Rico

Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA)

Conditions: Infantile-onset Spinal Muscular Atrophy

First Posted Date: 2016-08-12

Last Posted Date: 2021-04-05

Lead Sponsor: Biogen

Registration Number: NCT02865109

Locations: 🇳🇿
Auckland District Health Board ADHB, Grafton, Auckland, New Zealand
🇹🇷
Erciyes University Hospital, Kayseri, Anatolia, Turkey
🇳🇿
Auckland City Hospital, Grafton, Auckland, New Zealand

and more 4 locations

A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)

Phase 2

Terminated

Conditions: Cognitive Impairment Associated With Schizophrenia (CIAS)

Interventions: Drug: PF-04958242
Drug: placebo

First Posted Date: 2016-08-04

Last Posted Date: 2020-01-09

Lead Sponsor: Biogen

Target Recruit Count: 35

Registration Number: NCT02855411

Locations: 🇺🇸
Collaborative Neuroscience Network, LLC, Torrance, California, United States
🇺🇸
Atlanta Center For Medical Research, Atlanta, Georgia, United States
🇺🇸
Pillar Clinical Research, LLC, Dallas, Texas, United States

and more 12 locations

Home Terms & Conditions Privacy Policy